555 results about "In vitro diagnostic" patented technology

The invention provides a multi-channel one-core multi-detection integrated detection method, which is applied to the technical field of in-vitro diagnosis and comprises the following steps: acquiring time sequence original signals of blood routine, liver function and kidney function channels; obtaining a baseline stable primary signal through cross-channel baseline trend coupling and adaptive correction; adopting a machine learning model to identify interference components and performing component offset to obtain a decoupling signal; mapping the decoupling signal into a physiological parameter value and carrying out rationality test; when the low credible parameter exists, a rechecking mechanism is triggered; performing weighted fusion on the basis of the rationality test result and the recheck signal to obtain a comprehensive parameter set; and finally generating a comprehensive detection report containing the credibility score. Cooperative processing and fusion analysis of multi-channel detection signals are realized, and the accuracy and reliability of a detection result are remarkably improved through interference identification and a dynamic recheck mechanism.

The invention relates to the technical field of in-vitro diagnostic kits, and provides an apolipoprotein E4 detection kit and application thereof. The immunochromatography test paper comprises detection immunochromatography test paper, the detection immunochromatography test paper comprises a bottom plate, a sample pad, a combination pad, an NC membrane and a water absorption pad, the combination pad and the sample pad are sequentially arranged on one side of the NC membrane, and the water absorption pad is arranged on the other side of the NC membrane; the combination pad is marked with gold manganese oxide nanometer developing particles and an apolipoprotein APOE4 monoclonal antibody. According to the technical scheme, the problems of complicated operation, high cost, low detection sensitivity and weak specificity of apolipoprotein E4 detection in related technologies are solved.

The invention relates to the technical field of in-vitro diagnostic kits, in particular to carboxyl polystyrene microspheres, a preparation method and application of the carboxyl polystyrene microspheres in a kit for quantitatively detecting MxA. The preparation method of the carboxyl polystyrene microspheres comprises the steps that firstly, polystyrene microspheres with the surface rich in aldehyde groups are prepared through a soap-free emulsion polymerization method; then carrying out a Schiff alkali reaction with 2-aminoethyl methacrylate hydrochloride to carry out double bond modification on the surface of the microsphere, and meanwhile, improving the hydrophilicity of the microsphere by an ester group and an imino group; and finally, carrying out sulfydryl-double bond addition reaction on the polystyrene microspheres and mercaptosuccinic acid to generate the polystyrene microspheres rich in carboxyl on the surfaces. The carboxyl polystyrene microspheres prepared by the invention can improve the binding efficiency of latex and an MxA antibody, so that the detection sensitivity is improved, the purpose of high-sensitivity quantitative detection of MxA protein can be achieved, and the detection time is greatly shortened.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a detection kit and a detection method for a pretumor marker. The kit comprises an elisa plate coated with a captured antibody, an HRP labeled antibody, an antigen standard substance, a washing solution, a developing solution and a stop solution, the capture antibody and the HRP labeled antibody are both prepared from a monoclonal antibody of the anti-SLC31A1 protein. According to the detection method of the kit for detecting the pretumor marker, the SLC31A1 protein content in human serum is detected through the kit, the specificity is high, a large batch of samples can be rapidly detected in a high-throughput mode, the cancer risk of a to-be-detected crowd can be effectively judged, and therefore relevant patients can find and treat the pretumor marker in advance, treatment prognosis is improved, and the death rate is reduced.

The application belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody specifically recognizing type II grass carp reovirus VP4 protein, a eukaryotic expression method and application. The S6 gene in GCRV-II encodes VP4 protein, the application transfects the target gene S6 into HEK293 cells for expression and purification, cooperates with Freund's adjuvant to immunize New Zealand white rabbits, and uses ELISA, single B cell screening and eukaryotic expression technology to obtain a rabbit-derived recombinant monoclonal antibody specifically recognizing GCRV-II VP4 protein. The antibody has strong specificity, provides support for further establishment of specific type II grass carp reovirus diagnosis technology, and has great application value for development of GCRV-II related scientific research.

The utility model provides a quantifiable detection consumable and detection equipment, and relates to the in vitro diagnostic technology, the quantifiable detection consumable comprises a sample tube with a cavity and a reaction tube communicated with the sample tube, the reaction tube is provided with a reaction cavity and a sealing film for sealing the reaction cavity; the piston structure is arranged in the cavity; a first limiting structure used for limiting the piston structure to the first position and a second limiting structure used for limiting the piston structure to the third position are further arranged on the inner wall of the sample tube, the piston structure pierces the sealing film when moving to the third position from the first position, and the treatment liquid quantitatively flows into the reaction cavity; the piston structure is used for puncturing the isolating membrane isolated between the cavity and the reaction cavity, so that the treatment liquid enters the reaction cavity, the step of container replacement is omitted, meanwhile, the piston structure is pushed to move by a preset stroke, it is ensured that the mixed solution quantitatively flows into the reaction cavity, and it is avoided that excessive mixed solution enters the reaction cavity, and the detection result is affected.

A method for automatically generating a research and development proposal for an in vitro diagnostic kit, performed by a server for automatically generating the research and development proposal, includes: acquiring an initial proposal including intended use information for the kit; providing the acquired initial proposal to a pre-trained language model; acquiring a specification (spec) for the kit from the language model receiving the initial proposal, wherein the acquired specification for the kit includes at least one of a technical specification to be used for the research and development of the kit, a resource specification for the research and development, a design specification for the kit, a regulatory approval specification that is needed to meet for approval, and a performance specification for the kit; and controlling to generate the research and development proposal for the kit including the acquired specification and the intended use information for the kit.

The invention discloses a creatinine detection device, and belongs to the field of in-vitro diagnosis equipment. The creatinine detection device comprises a substrate, a reagent 1 assembly and a reagent 2 assembly, the reagent 1 assembly comprises a flow pad, an enzyme pad and a blood filter membrane, the reagent 2 assembly comprises a start inhibition layer, a separation layer and a color development layer, the reagent 1 assembly and the reagent 2 assembly are stored in a non-contact mode in a normal state, and the reagent 1 assembly and the reagent 2 assembly are in contact to start a reaction during testing; the separation layer contains perfluorooctane sulfonic acid and / or perfluorooctane carboxylic acid. According to the creatinine detection device provided by the invention, interference of endogenous ammonia can be eliminated, the diffusivity of the ammonia is improved, and the detection sensitivity is improved.

A process for ultrasensitive in vitro detection and / or quantification of a substance of interest in a sample is performed by detecting the luminescence emission by photoluminescent inorganic nanoparticles. The process includes (i) use of photoluminescent particles comprising a photoluminescent inorganic nanoparticle consisting of a crystalline matrix having at least 103 rare-earth ions, and coupled to a targeting agent for the substance to be analyzed, under conditions conducive to their association with the sample substance to be analyzed; (ii) exciting the rare-earth ions of the particles by an illumination device having a power of at least 50 mW and an excitation intensity of at least 1 W / cm2; (iii) detecting the luminescence emission by the particles after single-photon absorption; and (iv) determining the presence and / or concentration of the substance by interpreting said luminescence measurement. This process can be used for in vitro diagnostic purposes and as an in vitro diagnostic kit.

A biodegradable and mouldable cassette for lateral flow assay device, and a lateral flow assay device comprising said cassette, and a kit comprising such a lateral flow assay device, for in vitro diagnostics of a biological sample comprising a diagnostic test strip inserted into the cassette. The cassette comprises a first cassette part and a second cassette part coupled to each other and defining a test chamber there between containing the diagnostic test strip. The cassette is made of a biodegradable material and at least one of the first cassette part and second cassette part is made of injection mouldable material, in particular gelatin or a gelatin composition.

The invention discloses a pipetting amount testing method and system of in-vitro diagnostic equipment and a storage medium, and particularly relates to the technical field of in-vitro diagnostic equipment, and the pipetting amount testing method comprises the steps of S1, multi-modal sensing data acquisition and preprocessing, S2, data fusion processing, S3, adaptive calibration, and S4, dynamic monitoring and report generation. According to the invention, the flow velocity and volume change of the liquid can be accurately calculated, bubble interference is effectively eliminated, adaptive calibration is realized, real-time monitoring and abnormity positioning are realized, a calibration report is generated and safely stored and traced, meanwhile, the optimal system performance is guaranteed, and the accuracy, reliability, intelligent degree and data safety of the pipetting amount test of the in-vitro diagnostic equipment are improved.

The invention relates to the technical field of in-vitro diagnostic kits, in particular to hollow porous monodisperse carboxyl polystyrene microspheres, a preparation method and application of the hollow porous monodisperse carboxyl polystyrene microspheres in a kit for quantitatively detecting MxA. The preparation method of the microspheres comprises the steps that firstly, hydrophilic polystyrene microspheres are prepared to serve as stable particles; then fully mixing the Pickering particles with a first oil phase to form Pickering stable particles; then a surfactant and a second oil phase are added, the mixed system is stirred at a high speed, and the second oil phase permeates into the surfaces or pores of Pickering stable particles through interface interaction and molecular diffusion; under the action of an initiator, the polymeric monomers are subjected to a polymerization reaction, the low-boiling-point organic solvent is evaporated out along with temperature rise, and a polymer with a core part of a hollow structure and a shell layer of a porous structure is formed; and adding a carboxyl-containing functional monomer to form a hydrophilic polymer chain on the surface of the polymer, thereby finally obtaining the hollow porous monodisperse carboxyl polystyrene microspheres.

A diagnostic device with an improved optical system is disclosed. The disclosed in vitro diagnostic device has a housing with an inner bottom surface having an arc shape that rises upward from one side where the light source is arranged to the other side where the cartridge sensing surface is arranged. This device may include light sources with different wavelengths arranged on one side of the lower housing. Additionally, it may include an upper housing that is coupled to the upper surface of the lower housing and has a cartridge insertion space for a cartridge with a plurality of wells. The upper housing includes an observation window that covers at least the plurality of sensing hole areas to allow optical observation of the inside of the wells.

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and / or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

The invention discloses a monoclonal antibody which is specifically combined with a microtubule associated protein tau (microtubule associated protein with 217 Thrphorylation, pTau217) of which the 217 site is phosphorylated by threonine, and a preparation method of the monoclonal antibody. The invention provides an amino acid sequence of a variable domain of the monoclonal antibody, and an amino acid sequence of a complementary determining region (CDR) contained in the amino acid sequence of the variable domain of the monoclonal antibody. The monoclonal antibody disclosed by the invention has the capability of specifically recognizing and remarkably combining pTau217, and can be used for developing and producing pTau217 clinical in vitro diagnosis (IVD) medical equipment products based on an immunological detection principle as a reagent raw material.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

A personalized medical method for treating amyotrophic lateral sclerosis (ALS), comprising screening out a subpopulation of ALS patients having highly immunologically active causes, and administering a therapeutically effective amount of a Janus kinase (JAK) inhibitor to the patients screened out thereby. Also provided are the use of a corresponding JAK inhibitor, an in vitro diagnostic method for screening patients, a kit, and a computer-implemented method. After patients screened out by means of the method are treated with a JAK inhibitor (such as tofacitinib), the level of a nerve damage marker is significantly reduced, and clinical functions are stabilized or improved, and therefore the present invention shows a good therapeutic prospect.

The present invention relates to a preparation method of magnetic carbon quantum dots with high relaxation rate, comprising the following steps: (1) dissolving sp<supgt;3< / supgt> precursor and sp<supgt;2< / supgt> precursor in a solvent for solvothermal reaction to obtain a first mixed system; (2) redispersing the reaction product in water, performing suction filtration, and then adding gadolinium ions for hydrothermal reaction to obtain a second mixed system; (3) performing dialysis on the second mixed system to obtain magnetic carbon quantum dots with high relaxation rate. During the preparation process of the present invention, the reaction conditions are controllable and the product purification is simple. The obtained carbon quantum dots not only have the paramagnetism of gadolinium ions but also have the fluorescence characteristics of carbon quantum dots, and can be used as a probe for nuclear magnetic resonance relaxation-fluorescence dual-mode in vitro diagnostic technology to improve the accuracy of in vitro diagnostic technology.

The invention provides a lipoprotein sub-component phospholipid detection kit, and belongs to the field of in-vitro diagnostic reagents, and in particular, the lipoprotein sub-component phospholipid detection kit provided by the invention comprises a reaction reagent, the reaction reagent comprises a buffer solution, a surfactant, magnesium chloride, 4-aminoantipyrine, N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3, 3, 4-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5-trimethyl-1, 3, 5- The preservative is prepared from 2, 5-dimethoxyaniline sodium salt, phospholipase D, choline oxidase, peroxidase, ascorbic acid oxidase, a protective agent and a third preservative. The lipoprotein subfraction phospholipid detection kit provided by the invention can be used for determining the content of lipoprotein subfraction phospholipid by using a VAP system, simultaneously realizes simultaneous detection of a plurality of lipoprotein subfraction phospholipid items for the first time, and has the advantages of high precision and high accuracy.

An automated method of washing a fluidic system 210 of an IVD analyzer 200 from a previous fluid is disclosed, the fluidic system 210 comprising at least one fluidic path 211, 213, 215. The method comprises controlling by a controller 250 a pump 240 and at least one fluid-selection valve 230 for pumping a wash fluid 221 and / or air 232 through the at least one fluidic path, wherein in a time-priority mode 10 the method comprises pumping at higher speed air, in a first step 11, in order to remove the previous fluid from the at least one fluidic path, and wash-fluid plugs alternated to air plugs, in a second step 12, in order to wash out residuals of the previous fluid, and wherein in a wash-fluid-priority mode 20 the controller 250 is configured to operate according to either a sample-wash mode 30 if the previous fluid is a sample 2 or according to an other-fluid-wash mode 40 if the previous fluid is any fluid other than a sample 2, wherein in the sample-wash mode 30 the method comprises pumping air at lower speed, in a first step 31, in order to remove the previous fluid from the at least one fluidic path, pumping at least one wash-fluid plug at higher speed, in a second step 32, and pumping wash-fluid plugs alternated to air plugs at lower speed, in a third step 33, in order to wash out residuals of the previous fluid, and wherein in the other-fluid-wash mode 40 the method comprises pumping air at lower speed, in a first step 41, in order to remove the previous fluid from the at least one fluidic path and pumping wash-fluid plugs alternated to air plugs at lower speed, in a second step 42, in order to wash out residuals of the previous fluid.

1. The name of the design product: pathological scanner. 2. The use of the design product: the design product is used for in-vitro diagnosis and scientific research. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: design 1 perspective view 1. 5. Design 1 is designated as the basic design.

Provided are a test reagent that reduces non-specific adsorption and is capable of detecting a low-concentration target substance, and a detection method including using the test reagent. The test reagent is a test reagent for in vitro diagnosis, and comprises: a thiourea compound; and resin particles, wherein the resin particles each have a sulfur element.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TREM2 in preparation of a diagnostic kit for chronic kidney disease osteoporosis. The invention finds that the TREM2 signal channel is closely related to the common pathological background of chronic kidney disease and osteoporosis. Therefore, the TREM2 can be used as an expression characteristic and a molecular diagnosis marker in the chronic kidney disease-related osteoporosis, so that the chronic kidney disease-related osteoporosis can be subjected to early diagnosis. On the basis, the invention provides application of the TREM2 detection reagent in preparation of the chronic kidney disease osteoporosis diagnosis kit, and the application prospect is good.

The present invention concerns a method for the in vitro diagnosis of neurodegenerative metabolic diseases able to simultaneously identify biomarkers characteristic of a large number neurodegenerative metabolic diseases.

The amount of certain metabolomic markers from the lipid metabolism can be used for the highly specific and sensitive in-vitro diagnosis of ADHD.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

The invention relates to a reagent disc control method and device, a computer readable storage medium, computer equipment and a system, and belongs to the field of in vitro diagnos.The method comprises the steps that a to-be-controlled reagent disc is displayed in a reagent disc management interface, reagent rings in the to-be-controlled reagent disc correspond to entity reagent rings in a target entity reagent disc in a one-to-one mode, and the entity reagent rings in the target entity reagent disc correspond to the reagent rings in the target entity reagent disc in a one-to-one mode; reagent ring operation controls in one-to-one correspondence with the reagent rings are further displayed in the interface, in response to unlocking triggering operation on the reagent ring operation controls, the reagent rings corresponding to the reagent ring operation controls corresponding to the operation are switched to be in an unlocking state, and the entity reagent rings corresponding to the reagent rings are controlled to be switched to be in an experiment stopping state. The entity reagent rings corresponding to the reagent rings still in the locking state maintain the experiment state. Therefore, different entity reagent rings can be respectively controlled through different reagent ring operation controls, independent control of each entity reagent ring is realized, mutual influence is avoided, and the experiment efficiency is effectively improved.

The invention is applicable to the field of in-vitro diagnostic equipment, and discloses a sample analyzer. The sample analyzer comprises a first consumable supply device, a second consumable supply device, a sample distribution device, a nucleic acid extraction device, a pipetting device, an amplification device and a detection device, wherein the first consumable supply device is at least used for providing an amplification reaction container; the second consumable supply device is at least used for providing a nucleic acid extraction container, and the second consumable supply device is arranged below or above the first consumable supply device; the sample distribution device is used for sucking a sample and dispensing the sample into the nucleic acid extraction container provided by the second consumable supply device; the nucleic acid extraction device is used for performing nucleic acid extraction on liquid at least containing a sample to obtain a nucleic acid extracting solution; the pipetting device is used for sucking a nucleic acid extracting solution and separately injecting the nucleic acid extracting solution into the amplification reaction container provided by the first consumable supply device; and the amplification device is used for amplifying the liquid containing the nucleic acid extracting solution. The horizontal occupied space of the sample analyzer is reduced.

This utility model relates to the field of in vitro diagnostic automation equipment technology, and discloses a feeding slide structure and a testing analyzer, including: a hopper having an inlet end and an outlet end. A slide is set at the outlet end and partially extends into the hopper. A receiving component is set at the part of the slide extending into the hopper, and is located at the landing point of the reaction cup after entering the hopper. The cup-guiding structure includes a guiding plate located above the slide, one end of which is rotatably set close to the outlet end, and the other end extends towards the slide. The guiding plate is used to correct the posture of the reaction cup entering the slide. The feeding slide structure provided by this utility model improves the correction efficiency of the reaction cup through the receiving component, reduces the time the reaction cup takes to pass through the hopper, can adapt to the feeding requirements of high-speed equipment, reduces the probability of cup stacking and jamming, and can also prevent malfunctions caused by cup overflow through the guiding plate.